David Greenspan’s Alnylam Pharmaceuticals ALNY Stock Holding History

David Greenspan’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-213,000	Closed	-$31M	–	31
2020 Q3	$31M	Sell	213,000 -371,000	-64%	-$52.7M	1.76%	16
2020 Q2	$86.5M	Sell	584,000 -134,000	-19%	-$18.1M	5.1%	11
2020 Q1	$78.2M	Sell	718,000 -97,000	-12%	-$11.2M	5.99%	6
2019 Q4	$93.9M	Buy	815,000 +200,000	+33%	+$19.9M	5.06%	9
2019 Q3	$49.5M	Hold	615,000	–	–	3.27%	11
2019 Q2	$44.6M	Buy	615,000 +135,000	+28%	+$10.4M	2%	12
2019 Q1	$44.9M	Hold	480,000	–	–	3.63%	10
2018 Q4	$35M	Hold	480,000	–	–	3.94%	11
2018 Q3	$42M	Hold	480,000	–	–	5.64%	9
2018 Q2	$47.3M	Buy	480,000 +105,000	+28%	+$10.4M	3.57%	11
2018 Q1	$44.7M	Sell	375,000 -72,000	-16%	-$9.28M	2.85%	13
2017 Q4	$56.8M	Sell	447,000 -114,000	-20%	-$14.3M	5.59%	7
2017 Q3	$65.9M	Sell	561,000 -574,000	-51%	-$49M	3.47%	12
2017 Q2	$90.5M	Sell	1,135,000 -865,000	-43%	-$55.3M	3.44%	11
2017 Q1	$103M	Hold	2,000,000	–	–	5.02%	11
2016 Q4	$74.9M	Buy	2,000,000 +775,000	+63%	+$32.4M	2.28%	12
2016 Q3	$83M	Buy	1,225,000 +90,000	+8%	+$6.35M	1.38%	7
2016 Q2	$63M	Hold	1,135,000	–	–	4.93%	10
2016 Q1	$71.2M	Buy	1,135,000 +410,000	+57%	+$27.3M	5.53%	8
2015 Q4	$68.3M	Buy	725,000 +130,000	+22%	+$12.1M	7.38%	7
2015 Q3	$47.8M	Sell	595,000 -86,759	-13%	-$9.64M	5.48%	7
2015 Q2	$81.7M	Sell	681,759 -173,241	-20%	-$20.7M	8.93%	8
2015 Q1	$89.3M	Hold	855,000	–	–	5.63%	9
2014 Q4	$82.9M	Hold	855,000	–	–	5.8%	9
2014 Q3	$66.8M	Buy	855,000 +257,000	+43%	+$16.6M	3%	12
2014 Q2	$37.8M	Buy	598,000 +186,460	+45%	+$11.1M	1.06%	16
2014 Q1	$27.6M	Sell	411,540 -588,460	-59%	-$45.6M	2.09%	13
2013 Q4	$64.3M	Sell	1,000,000 -260,000	-21%	-$15.5M	2.22%	15
2013 Q3	$80.7M	Buy	1,260,000 +210,000	+20%	+$10.5M	4.2%	13
2013 Q2	$32.5M	Buy	+1,050,000	New	+$27.9M	1.76%	13

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

David Greenspan's ALNY Position: Q4 2020 in Review

David Greenspan sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 213,000 shares — an estimated $31M sold.

David Greenspan first reported a position in ALNY in Q2 2013 and held it in 30 quarters. The position peaked at $103M in Q1 2017. 375 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

David Greenspan reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
David Greenspan sold 213,000 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $31M.
David Greenspan first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 30 quarters.
David Greenspan's Alnylam Pharmaceuticals position peaked at $103M in Q1 2017.
375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Slate Path Capital's 13F filing for Q4 2020, filed 16 Feb 2021.